Dutch inspectorate publishes report on June 2026 inspection of Corcept Therapeutics Netherlands in Hoofddorp
The IGJ has released a report from its supervisory visit to Corcept's Dutch entity, though the source text does not disclose the findings or any required improvements.
The Dutch Health and Youth Care Inspectorate (IGJ) has published a report on a supervisory inspection visit to Corcept Therapeutics Netherlands B.V. in Hoofddorp. The visit took place in June 2026, and the document was listed in the inspectorate's supervision documents on 28 October 2026.
According to the summary on file, the report sets out the inspectorate's assessment and any improvement measures it requires of the company. The source text available to VigiEye, however, consists only of a page heading and does not describe what the inspectors found, which area of compliance was examined, or whether any deficiencies were recorded.
It is therefore not possible to say whether the inspection concerned pharmacovigilance, good distribution practice or another area of GxP. No details have been given on the severity of any observations, on follow-up actions or on deadlines for the company.
As general context, national inspectorates such as the IGJ publish inspection reports as part of their supervisory transparency, and these documents normally record the inspectors' observations and the corrective actions expected of the inspected organisation. Readers should consult the full report on the IGJ website for the substantive conclusions.
What it means for your team
- The substance of the report is not available in the source text, so no conclusions about compliance status should be drawn without reading the full document.
- Pharmacovigilance and quality teams with business links to Corcept Therapeutics Netherlands may wish to review the report for any implications for shared processes or agreements.
- Companies with Dutch operations can use published IGJ reports as a guide to current inspection practice and expectations.
Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial